JP2012515184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515184A5 JP2012515184A5 JP2011545725A JP2011545725A JP2012515184A5 JP 2012515184 A5 JP2012515184 A5 JP 2012515184A5 JP 2011545725 A JP2011545725 A JP 2011545725A JP 2011545725 A JP2011545725 A JP 2011545725A JP 2012515184 A5 JP2012515184 A5 JP 2012515184A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- bibw2992
- bibf1120
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 27
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 15
- 229960004378 nintedanib Drugs 0.000 claims 15
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 12
- 229960001686 afatinib Drugs 0.000 claims 12
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 7
- 230000003442 weekly effect Effects 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09150565 | 2009-01-14 | ||
| EP09150565.1 | 2009-01-14 | ||
| PCT/EP2010/050338 WO2010081817A1 (en) | 2009-01-14 | 2010-01-13 | Method for treating colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515184A JP2012515184A (ja) | 2012-07-05 |
| JP2012515184A5 true JP2012515184A5 (enExample) | 2013-02-28 |
Family
ID=41666486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545725A Pending JP2012515184A (ja) | 2009-01-14 | 2010-01-13 | 大腸がんの治療方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120157472A1 (enExample) |
| EP (1) | EP2387401A1 (enExample) |
| JP (1) | JP2012515184A (enExample) |
| WO (1) | WO2010081817A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP45508A (en) | 1999-06-21 | 2011-02-10 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| EP3173084B1 (en) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| EP1948180B1 (en) * | 2005-11-11 | 2013-03-13 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
| PL1981863T3 (pl) | 2006-01-26 | 2013-03-29 | Boehringer Ingelheim Int | Sposób wytwarzania pochodnych chinazoliny podstawionych przez ugrupowanie aminokrotonyloaminowe |
| SI2068880T1 (sl) * | 2006-09-18 | 2012-08-31 | Boehringer Ingelheim Int | Postopek za zdravljenje raka, ki vsebuje mutacije EGFR |
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| PE20100252A1 (es) * | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| RS57142B1 (sr) * | 2008-06-06 | 2018-07-31 | Boehringer Ingelheim Int | Farmaceutski dozni oblik u vidu kapsule koji sadrži formulaciju suspenzije indolinon derivata |
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| HRP20191005T1 (hr) | 2009-07-06 | 2019-08-23 | Boehringer Ingelheim International Gmbh | Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| AU2013337264B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| AU2014207342C1 (en) | 2013-01-18 | 2019-04-04 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3121152A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie" |
| US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| EP1948180B1 (en) | 2005-11-11 | 2013-03-13 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
| EP3173084B1 (en) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| EP1870400A1 (en) * | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
-
2010
- 2010-01-13 WO PCT/EP2010/050338 patent/WO2010081817A1/en not_active Ceased
- 2010-01-13 US US13/142,453 patent/US20120157472A1/en not_active Abandoned
- 2010-01-13 JP JP2011545725A patent/JP2012515184A/ja active Pending
- 2010-01-13 EP EP10700174A patent/EP2387401A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515184A5 (enExample) | ||
| FI3494972T3 (fi) | Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon | |
| JP2012255026A5 (enExample) | ||
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
| JP2013155188A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2013541583A5 (enExample) | ||
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| JP2016539156A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| WO2008011426A3 (en) | Methods and medicaments for administration of ibuprofen | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013518124A5 (enExample) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| JP2015507020A5 (enExample) | ||
| JP2012041314A5 (enExample) | ||
| JP2006517557A5 (enExample) | ||
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2014503589A5 (enExample) |